Related Experiment Video
Updated: Jun 12, 2026
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Transmitter deficits in Alzheimer's disease
J Hardy1, R Adolfsson, I Alafuzoff
1Umeå Dementia Research Group, Departments of Pathology, Psychiatry and Geriatric Medicine, University of Umeå, Umeå Sweden.
Neurochemistry International
|May 25, 2010
Summary
Alzheimer's disease selectively damages specific neurotransmitter pathways, including cholinergic, noradrenergic, and serotoninergic systems. Understanding these targeted neuronal losses is key to comprehending the disease's pathology and symptoms.
Area of Science:
- Neuroscience
- Neuropathology
- Neurochemistry
Background:
- Alzheimer's disease (AD) is characterized by progressive neurodegeneration.
- Specific neurotransmitter systems are known to be affected in AD, but the precise patterns and implications require further elucidation.
Purpose of the Study:
- To review the established patterns of neurotransmitter pathway deficits in Alzheimer's disease.
- To correlate these pathway losses with clinical symptoms and neuropathology.
- To compare AD findings with other dementing disorders to identify commonalities.
Main Methods:
- Review of existing literature on neurotransmitter pathway deficits in Alzheimer's disease.
- Analysis of biochemical and histological findings in AD tissues.
- Comparative analysis with data from other dementing disorders.
Main Results:
- Established deficits in cholinergic, noradrenergic, and serotoninergic pathways are confirmed.
- Cortical somatostatin interneurons are affected; dopaminergic neurons may be secondarily impacted.
- Neuronal damage is selective, not a generalized atrophy, with some neurons being spared.
- Pathway-specific losses correlate with clinical symptomatology and pathology.
Conclusions:
- Alzheimer's disease involves selective neurotransmitter pathway degeneration, not global neuronal loss.
- Understanding these specific deficits is crucial for explaining AD's clinical presentation and pathology.
- Comparative analysis suggests common features among dementing disorders, potentially related to neuronal pathogenesis.
Related Concept Videos
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...